Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
